Adaptive Biotechnologies (NASDAQ:ADPT) Stock: Insider Julie Rubinstein Sells 11,881 Shares

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) COO Julie Rubinstein sold 11,881 shares of the stock in a transaction on Monday, November 9th. The stock was sold at an average price of $30.12, for a total value of $357,855.72. Following the transaction, the chief operating officer owned 377,802 shares of the company’s stock, valued at $11,379,396.24. The trade was a 3.05% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Julie Rubinstein also recently made the following trade(s):

• On Thursday, November 5th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $26.53, for a total value of $315,202.93.
• On Friday, October 30th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $26.73, for a total value of $317,579.13.
• On Monday, November 2nd, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $25.47, for a total transaction of $302,609.07.
• On Wednesday, October 28th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $28.45, for a total transaction of $338,014.45.
• On Monday, October 26th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $26.04, for a total transaction of $309,381.24.
• On Friday, October 23rd, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $24.98, for a total transaction of $296,787.38.
• On Monday, October 19th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $24.05, for a total transaction of $285,738.05.
• On Wednesday, October 21st, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $25.41, for a total transaction of $301,896.21.
• On Thursday, October 15th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $25.61, for a total transaction of $304,272.41.
• On Tuesday, October 13th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $25.50, for a total transaction of $302,965.50.

Adaptive Biotechnologies Price Performance

Adaptive Biotechnologies stock traded down $0.90 during mid-day trading on Tuesday, reaching $29.36. The company’s stock had a trading volume of 1,849,454 shares, compared to its average volume of 2,155,608. The firm’s fifty day moving average price is $26.61 and its two-hundred day moving average price is $19.97. The company has a quick ratio of 3.87, a current ratio of 3.97 and a debt-to-equity ratio of 1.82. Adaptive Biotechnologies Corporation has a 12-month low of $12.00 and a 12-month high of $30.81.

Adaptive Biotechnologies (NASDAQ:ADPT) last posted its earnings results on Wednesday, November 4th. The company reported $0.02 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.12. Adaptive Biotechnologies had a negative return on equity of 23.95% and a negative net margin of 23.67%. The firm had revenue of $83.90 million for the quarter, compared to the consensus estimate of $71.57 million. During the same quarter in the prior year, the business posted $0.06 earnings per share. The business’s quarterly revenue was down 10.7% on a year-over-year basis. As a group, equities analysts forecast that Adaptive Biotechnologies Corporation will post -0.34 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on ADPT. BTIG Research increased their price objective on Adaptive Biotechnologies from $25.00 to $34.00 and gave the stock a “buy” rating in a report on Tuesday, September 22nd. The Goldman Sachs Group assumed coverage on Adaptive Biotechnologies in a report on Tuesday, September 29th. They set a “buy” rating and a $35.00 target price for the company. Guggenheim lifted their target price on Adaptive Biotechnologies from $32.00 to $34.00 and gave the company a “buy” rating in a report on Tuesday. Morgan Stanley upped their price target on Adaptive Biotechnologies from $22.00 to $27.00 and gave the company an “equal weight” rating in a research report on Monday, October 12th. Finally, National Bank Financial set a $34.00 price target on shares of Adaptive Biotechnologies in a report on Tuesday, September 22nd. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Adaptive Biotechnologies presently has an average rating of “Moderate Buy” and an average target price of $30.31.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of ADPT. Nykredit A S bought a new stake in Adaptive Biotechnologies during the second quarter valued at approximately $31,000. Allworth Financial LP purchased a new position in Adaptive Biotechnologies in the 2nd quarter worth approximately $35,000. KBC Group NV bought a new position in shares of Adaptive Biotechnologies in the 1st quarter worth $45,000. Integrated Wealth Concepts LLC bought a new position in shares of Adaptive Biotechnologies in the 2nd quarter worth $46,000. Finally, Assetmark Inc. increased its stake in Adaptive Biotechnologies by 46.4% in the first quarter. Assetmark Inc. now owns 4,421 shares of the company’s stock valued at $61,000 after acquiring an additional 1,401 shares during the last quarter. 99.17% of the stock is currently owned by institutional investors.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a biotechnology company focused on using the human immune system to diagnose and treat disease. Based in Seattle, Washington, the company develops technologies that sequence and analyze immune cells and their receptors, generating data for clinical testing, research and drug development. Its products include immunoSEQ, a platform used by researchers and biopharmaceutical companies to study immune responses, and clonoSEQ, a clinical test that detects and monitors minimal residual disease in certain blood cancers.